Entering text into the input field will update the search result below

Redx Pharma inks research pact with Jazz Pharma for cancer

Sep. 09, 2020 8:02 AM ETJazz Pharmaceuticals plc (JAZZ) StockJAZZBy: Vandana Singh, SA News Editor
  • Jazz Pharmaceuticals (NASDAQ:JAZZ) has signed a research collaboration agreement with Redx Pharma to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway.
  • Under the terms of the agreement, Jazz will make an upfront payment to Redx of $10M, followed by another $10M in year two, provided research work is continuing.
  • Redx will be responsible for research and preclinical development activities up to Investigational New Drug (IND) submission.
  • Following delivery of an IND-ready molecule, Redx will be eligible to receive up to a further $200M in milestone payments for each program. After IND submission, Jazz will be responsible for further development, manufacturing, regulatory activities and commercialization.
  • Redx is also eligible to receive tiered sales-based royalties in mid-single digit percentages.

Recommended For You

More Trending News

About JAZZ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
JAZZ--
Jazz Pharmaceuticals plc